Spun out as the healthcare company XenoVida Ltd....
The current world-wide obesity, metabolic syndrome and diabetes crisis threatens to reverse recent improvements in lifespan and overwhelm global healthcare budgets. Our analysis of these related disorders demonstrated that the causes are a combination of multiple genetic and environmental factors and that for the majority of people the current advice of “eat less and exercise more” is not effective. Consequently a fresh multi-faceted approach that puts the science of these disorders at its core is not only highly desirable but necessary.
Using our collective experience in neuroscience, immuno-inflammation, metabolism, psychology and nutrition, an approach centred on biochemical and behavioural profiling was designed. This provides a comprehensive series of biomarkers of risk and response. A programme focused on improving health, with body weight as a secondary outcome, comprising individualised dietary advice, exercise and behavioural interventions is tracked with concomitant body composition measures.
A pilot phase has been completed demonstrating positive data in a number of individuals. Beneficial changes in blood lipids and laso in other health biomarkers has been matched by weight loss which has been a reduction in fat mass and maintenance of muscle mass and improved health status. This data has enabled funding for future development and expansion. Our multi-disciplinary approach to health and weight management shows great promise and, in 2017, has been spun out as the healthcare company XenoVida Ltd (www.xenovida.com).
Chesterford Research Park, Little Chesterford, Saffron Walden, CB10 1XL